Clinical trial NCT01850108: Non-Myeloablative Conditioning and Bone Marrow Transplantation
Official title: A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other Hemoglobinopathies
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Sickle Cell Disease
Hemoglobinopathies
Lead sponsor: Vanderbilt-Ingram Cancer Center
Sponsor class: OTHER
First posted: 2013-05-09
Enrollment: 26
Sex: ALL
Minimum age (years): 1
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Allogeneic blood or marrow transplantation (alloBMT) is a curative therapy for a variety of hematologic disorders, including sickle cell disease and thalassemia. Even when it is clear that alloBMT can give to these patients an improvement in their disease, myeloablative transplants have important toxicities and mortalities associated. The lack of suitable donors continues to be a limit to access to transplantation. Substantial progress has been made recently in the development of pre-treatment regimens that facilitate the sustained engraftment of donor marrow with reduced toxicity. Most of these regimens incorporate highly immunosuppressive drugs, which allow the reduction or elimination of myeloablative agents or total body irradiation without endangering the sustained engraftment of HLA-identical allogeneic stem cells. Preliminary results of non-myeloablative allogeneic stem cell transplantation suggest that the procedure can be performed in patients who are ineligible for myeloablative alloBMT, and that sustained remissions of several hematologic malignancies can be obtained.


Eligibility criteria: RECIPIENT INCLUSION CRITERIA

* Patients who are ineligible for BMT from an HLA-matched sibling donor can proceed to a haplo-BMT. Patients with an HLA-matched related donor will proceed to a matched BMT.
* Age 1-70 years
* Good performance status (ECOG 0 or 1; Karnofsky and Lansky 70-100)
* Patients and donors must be able to sign consent forms. First degree relative should be willing to donate
* Patients must be geographically accessible and willing to participate in all stages of treatment.
* Eligible diagnoses: Patients with sickle cell anemia such as sickle cell anemia (Hb SS), Hb Sβ° thalassemia, Hb Sβ+thalassemia, Hb SC disease, Hb SE disease, Hb SD disease, Hemoglobin SO- Arab disease HbS with hereditary persistence of fetal hemoglobin. Other significant hemoglobinopathies.

Plus one of the following:

* Attenuation of progressive disease (adults):
* Severe and debilitating vaso-occlusive pain despite hydroxyurea or regular blood transfusion therapy.
* Stroke and silent infarct; stroke or central nervous system event lasting more than 24 hours; MRI changes indicative of brain parenchyma damage and MRA evidence of cerebrovascular disease.
* Recurrent acute chest syndrome requiring exchange hospitalization.
* Chronic lung disease as defined by progressive restrictive disease irrespective of oxygen requirements.
* Chronic kidney disease, CKD stage II - IV
* Transfusion dépendent thalassemia

RECIPIENT EXCLUSION CRITERIA:

* Poor performance status (ECOG\>1).
* Poor cardiac function: left ventricular ejection fraction\<35%.
* Poor pulmonary function: FEV1 and FVC\<40% predicted.
* Pulmonary hypertension moderate to severe by echocardiographic standards.
* Poor liver function: direct bilirubin \>3.1 mg/dl
* HIV-positive
* Minor (donor anti-recipient) ABO incompatibility if an ABO compatible donor is available.
* Prior transfusions from donor or recipient if caused alloimmunization vs. donor cells.
* Women of childbearing potential who currently are pregnant (Beta-HCG+) or who are not practicing adequate contraception.
* Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow-up. However, patients with history of stroke and significant cognitive deficit,that would preclude giving informed consent or assent will not be excluded, if they have a family member or significant other with Power of Attorney to also consent of their behalf.

CRITERIA FOR DONOR ELIGIBILITY:

* Weight ≥ 20kg and age ≥ 18 years or per institutional guidelines
* Donors must meet the selection criteria as defined by the Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) and will be screened per the American Association of Blood Banks (AABB). (AABB guidelines and the recipients will be informed of any deviations.)
* HLA-haploidentical first-degree relatives of the patient. Participants must be HLA typed at high resolution using DNA based typing at HLA-A, -B, -C and DRB1 and have available: An HLA haploidentical first degree relative donor (parents, siblings or half siblings, or children) with 2, 3, or 4 (out of 8) HLA-mismatches who is willing and able to donate bone marrow. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch. The donor and recipient must be HLA identical for at least one antigen (using high resolution DNA based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C, and HLA-DRB1. Fulfillment of this criterion shall be considered sufficient evidence that the donor and recipient share one HLA haplotype, and typing of additional family members is not required.

When more than one donor is available, the donor with the lowest number of HLA allele mismatches will be chosen, unless there is HLA cross-match incompatibility or a medical reason to select otherwise, in which case donor selection is the responsibility of the PI, in consultation with the immunogenetics laboratory. In cases where there is more than one donor with the least degree of mismatch, donors will be selected based on the most favorable combination of:

* HLA compatibility in cross-match testing and
* ABO compatibility
* Donor age \<40 years
* Avoid female donors for male recipients and
* Avoid CMV mismatched donor-recipient transplants:

HLA cross-matching (in order of priority):

* Mutually compatible (no cross-matching antibodies)
* Recipient non-cross-reactive with donor, donor cross-reactive with recipient
* Mutually cross-reactive

ABO compatibility (in order of priority):

* Compatible
* Major incompatibility
* Minor incompatibility
* Major and minor incompatibility
* Donors will be selected to minimize HLA mismatch in the Host-versus-graft direction.
* Donors fulfilling the following criteria are ineligible for registration onto this study:
* All donors will be screened by hemoglobin electrophoresis; donors with a clinically significant hemoglobinopathy are ineligible. Sickle trait is acceptable.

Primary outcomes:
measure: Transplant-related Mortality (TRM)
timeFrame: at 1 year after BMT
Secondary outcomes:
measure: Number of Patients Who Developed Grade I-IV Acute Graft-vs.-Host Disease
timeFrame: 2 years
measure: Number of Patients With Donor Hematopoietic Chimerism in Peripheral Blood <95% at 6 Months After Mini-haploBMT
timeFrame: Up to approximately 180 after mini-haploBMT
measure: Number of Participants With Hematologic and Non-hematologic Toxicities Following minihaploBMT
timeFrame: Day 60 after BMT
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt-Ingram Cancer Center
state: Tennessee
city: Paris
country: France
facility: Saint-Louis Hospital
city: London
country: United Kingdom
facility: St Mary's Hospital
Study officials:
affiliation: Vanderbilt-Ingram Cancer Center
name: Adetola A Kassim, MD
role: PRINCIPAL_INVESTIGATOR
References: